Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goedele De Smedt

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Therapeutics|March 9, 2010
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adultsMonika Schöller-Gyüre, Thomas N Kakuda, Goedele De Smedt, et al.
Expert Review of Anti-Infective Therapy|May 12, 2015
Darunavir/cobicistat once daily for the treatment of HIVThomas N Kakuda, Herta Crauwels, Magda Opsomer, et al.
Antiviral Therapy|August 24, 2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Vanitha Sekar, et al.
The Annals of Pharmacotherapy|May 1, 2008
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteersMonika Peeters, Katrien Janssen, Thomas N Kakuda, et al.
Journal of Hepatology|November 13, 2012
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)Oliver Lenz, Leen Vijgen, Jan Martin Berke, et al.
Journal of Clinical Pharmacology|February 26, 2013
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, James Witek, et al.
Journal of Hepatology|February 14, 2012
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label studyChristophe Moreno, Thomas Berg, Tawesak Tanwandee, et al.
British Journal of Clinical Pharmacology|May 22, 2008
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Goedele De Smedt, et al.
Journal of Clinical Pharmacology|February 13, 2013
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteersThomas N Kakuda, Rodica Van Solingen-Ristea, Fatima Aharchi, et al.
AIDS (London, England)|January 7, 2010
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studiesJohan Vingerhoets, Lotke Tambuyzer, Hilde Azijn, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Therapeutics|March 9, 2010
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adultsMonika Schöller-Gyüre, Thomas N Kakuda, Goedele De Smedt, et al.
Expert Review of Anti-Infective Therapy|May 12, 2015
Darunavir/cobicistat once daily for the treatment of HIVThomas N Kakuda, Herta Crauwels, Magda Opsomer, et al.
Antiviral Therapy|August 24, 2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Vanitha Sekar, et al.
The Annals of Pharmacotherapy|May 1, 2008
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteersMonika Peeters, Katrien Janssen, Thomas N Kakuda, et al.
Journal of Hepatology|November 13, 2012
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)Oliver Lenz, Leen Vijgen, Jan Martin Berke, et al.
Journal of Clinical Pharmacology|February 26, 2013
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, James Witek, et al.
Journal of Hepatology|February 14, 2012
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label studyChristophe Moreno, Thomas Berg, Tawesak Tanwandee, et al.
British Journal of Clinical Pharmacology|May 22, 2008
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Goedele De Smedt, et al.
Journal of Clinical Pharmacology|February 13, 2013
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteersThomas N Kakuda, Rodica Van Solingen-Ristea, Fatima Aharchi, et al.
AIDS (London, England)|January 7, 2010
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studiesJohan Vingerhoets, Lotke Tambuyzer, Hilde Azijn, et al.
Pageof 4